Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...